Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Other Working Capital Changes (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Other Working Capital Changes for 6 consecutive years, with -$249795.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Working Capital Changes fell 295.95% to -$249795.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $359900.0, a 334.62% increase, with the full-year FY2024 number at $616523.0, up 1013.12% from a year prior.
  • Other Working Capital Changes was -$249795.0 for Q3 2025 at Inhibikase Therapeutics, down from -$43271.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.9 million in Q2 2021 to a low of -$2.8 million in Q4 2021.
  • A 5-year average of -$171075.0 and a median of -$43271.0 in 2025 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 5067.62% in 2021; the steepest drop was 87492.54% in 2021.
  • Inhibikase Therapeutics' Other Working Capital Changes stood at -$2.8 million in 2021, then skyrocketed by 52.38% to -$1.3 million in 2022, then skyrocketed by 88.6% to -$152699.0 in 2023, then skyrocketed by 504.21% to $617221.0 in 2024, then plummeted by 140.47% to -$249795.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Other Working Capital Changes are -$249795.0 (Q3 2025), -$43271.0 (Q2 2025), and $35745.0 (Q1 2025).